Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

被引:499
|
作者
Ogitani, Yusuke [1 ]
Hagihara, Katsunobu [2 ]
Oitate, Masataka [2 ]
Naito, Hiroyuki [3 ]
Agatsuma, Toshinori [1 ]
机构
[1] Daiichi Sankyo Co Ltd, Biol & Immunooncol Labs, Tokyo, Japan
[2] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Tokyo, Japan
[3] Daiichi Sankyo Co Ltd, Oncol Labs, Tokyo, Japan
关键词
Antibody-drug conjugate; bystander killing; HER2; T-DM; topoisomerase I inhibitor; BRENTUXIMAB VEDOTIN; GEMTUZUMAB OZOGAMICIN; TRASTUZUMAB EMTANSINE; CATHEPSIN-B; EXPRESSION; LYMPHOMA; THERAPY; PHASE-3; SAFETY;
D O I
10.1111/cas.12966
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window. DS-8201a is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate prepared using a novel linker-payload system with a potent topoisomerase I inhibitor, exatecan derivative (DX-8951 derivative, DXd). It was effective against trastuzumab emtansine (T-DM1)-insensitive patient-derived xenograft models with both high and low HER2 expression. In this study, the bystander killing effect of DS-8201a was evaluated and compared with that of T-DM1. We confirmed that the payload of DS-8201a, DXd (1), was highly membrane-permeable whereas that of T-DM1, Lys-SMCC-DM1, had a low level of permeability. Under a coculture condition of HER2-positive KPL-4 cells and negative MDA-MB-468 cells in vitro, DS-8201a killed both cells, whereas T-DM1 and an antibody-drug conjugate with a low permeable payload, anti-HER2-DXd (2), did not. In vivo evaluation was carried out using mice inoculated with a mixture of HER2-positive NCI-N87 cells and HER2-negative MDA-MB-468-Luc cells by using an in vivo imaging system. In vivo, DS-8201a reduced the luciferase signal of the mice, indicating suppression of the MDA-MB-468-Luc population; however, T-DM1 and anti-HER2-DXd (2) did not. Furthermore, it was confirmed that DS-8201a was not effective against MDA-MB-468-Luc tumors inoculated at the opposite side of the NCI-N87 tumor, suggesting that the bystander killing effect of DS-8201a is observed only in cells neighboring HER2-positive cells, indicating low concern in terms of systemic toxicity. These results indicated that DS-8201a has a potent bystander effect due to a highly membrane-permeable payload and is beneficial in treating tumors with HER2 heterogeneity that are unresponsive to T-DM1.
引用
收藏
页码:1039 / 1046
页数:8
相关论文
共 50 条
  • [21] Targeting the Human Epidermal Growth Factor Receptor 2 in Esophageal Cancer
    Almhanna, Khaldoun
    Meredith, Kenneth L.
    Hoffe, Sarah E.
    Shridhar, Ravi
    Coppola, Domenico
    CANCER CONTROL, 2013, 20 (02) : 111 - 116
  • [22] Human Epidermal Growth Factor Receptor 2 Testing: Where Are We?
    De, Pradip
    Smith, Brian R.
    Leyland-Jones, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) : 4289 - 4292
  • [23] Lapatinib: A Small-Molecule Inhibitor of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor-2 Tyrosine Kinases Used in the Treatment of Breast Cancer
    Tevaarwerk, Amye J.
    Kolesar, Jill M.
    CLINICAL THERAPEUTICS, 2009, 31 : 2332 - 2348
  • [24] Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
    van Mackelenbergh, Marion
    Loibl, Sibylle
    Untch, Michael
    Buyse, Marc
    Geyer, Charles E., Jr.
    Gianni, Luca
    Schneeweiss, Andreas
    Conte, Pierfranco
    Piccart, Martine
    Bonnefoi, Herve
    Jackisch, Christian
    Nekljudova, Valentina
    Tang, Gong
    Valagussa, Pinuccia
    Neate, Colin
    Gelber, Richard
    Poncet, Coralie
    Squifflet, Pierre
    Saad, Everardo D.
    Heinzmann, Dominik
    Denkert, Carsten
    Rastogi, Priya
    Cortes, Javier
    Guarneri, Valentina
    de Azambuja, Evandro
    Cameron, David
    Ismael, Gustavo
    Wolmark, Norman
    Cortazar, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16) : 2998 - 3008
  • [25] Human epidermal growth factor receptor 2 (HER2/neu) supraexpression in the mammary tumors
    Moise, M.
    Motoc, A.
    Raducan, Andreea
    Raducan, S.
    Niculescu, V.
    Niculescu, M.
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2011, 52 (03) : 1101 - 1105
  • [26] Genetic regulation of antibody responses to human epidermal growth factor receptor 2 in breast cancer
    Pandey, Janardan P.
    Namboodiri, Aryan M.
    Kurtenkov, Oleg
    Nietert, Paul J.
    HUMAN IMMUNOLOGY, 2010, 71 (11) : 1124 - 1127
  • [27] Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects
    Jorgensen, Jan Trost
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (16) : 4526 - 4535
  • [28] Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer
    Jiang, Dawei
    Im, Hyung-Jun
    Sun, Haiyan
    Valdovinos, Hector F.
    England, Christopher G.
    Ehlerding, Emily B.
    Nickles, Robert J.
    Lee, Dong Soo
    Cho, Steve Y.
    Huang, Peng
    Cai, Weibo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (08) : 1296 - 1305
  • [29] A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion
    Fichter, Christiane Daniela
    Przypadlo, Camilla Maria
    Buck, Achim
    Herbener, Nicola
    Riedel, Bianca
    Schaefer, Luisa
    Nakagawa, Hiroshi
    Walch, Axel
    Reinheckel, Thomas
    Werner, Martin
    Lassmann, Silke
    JOURNAL OF PATHOLOGY, 2017, 243 (04) : 481 - 495
  • [30] H2Mab-19, an anti-human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts
    Takei, Junko
    Kaneko, Mika Kato
    Ohishi, Tomokazu
    Kawada, Manabu
    Harada, Hiroyuki
    Kato, Yukinari
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (02) : 846 - 853